Rheumatoid Arthritis Drugs Market Size, Share, Industry, Forecast and Outlook (2024-2031)

<h2>Global Rheumatoid Arthritis Drugs Market&nbsp;is segmented By Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologics, Analgesics, Others) By Route of Administration (Oral, Parenteral, Others) By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)&nbsp;By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

<h3>Market Overview</h3>

<blockquote>
Global rheumatoid arthritis drugs market reached US$ YY&nbsp;million in 2023 and is expected to reach US$ YY&nbsp;million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
</blockquote>

Rheumatoid arthritis is a chronic inflammatory disorder that can affect more than just joints. In some people, the condition can damage a wide variety of body systems, including the skin, eyes, lungs, heart and blood vessels. It occurs in the joints on both sides of the body, which makes it different from other types of arthritis.

There is no cure for rheumatoid arthritis. However clinical studies indicate that remission of symptoms is more likely when treatment begins early with medications known as disease-modifying antirheumatic drugs (DMARDs) and Nonsteroidal anti-inflammatory drugs (NSAIDs). DMARDs can slow the progression of rheumatoid arthritis and save the joints and other tissues from permanent damage. Common DMARDs include methotrexate (Trexall, Otrexup, others), leflunomide (Arava), hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine). Corticosteroid medications, such as prednisone, reduce inflammation and pain and slow joint damage.

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Size&nbsp;
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2022-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Estimation Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2024-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Revenue Units
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Drug Class, Route of Administration and Distribution Channel
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For more details on this report - <a href="https://www.datamintelligence.com/download-sample/rheumatoid-arthritis-drugs-market" target="_blank">Request for Sample</a>

<h3>&nbsp;</h3>

<h3>Market Dynamics: Drivers</h3>

Rising innovative product launches&nbsp;

The rising innovative product launches are expected to drive the market over the forecast period. Innovative product launches bring new treatment options to the market by offering patients a broader range of choices to manage rheumatoid arthritis. The introduction of biosimilar versions represents another facet of innovation in the rheumatoid arthritis drugs market. Biosimilars offer comparable efficacy and safety to their reference products at lower costs, expanding access to treatment and generating cost savings for healthcare systems, patients and payers.

For instance, on March 01, 2023, Enzene Biosciences announced the commercial release of its biosimilar for Adalimumab, a drug used to treat Ankylosing spondylitis and rheumatoid arthritis. Enzene&rsquo;s continuous manufacturing platform significantly reduces costs and the company expects to improve access to treatment for millions of patients across India. Enzene&rsquo;s novel platform offers higher productivity than traditional manufacturing processes, further reducing costs.

Ongoing research and clinical trials into the pathophysiology of rheumatoid arthritis continue to identify new therapeutic targets, driving innovation in drug discovery and development. Targeting specific immune pathways or cytokines implicated in RA pathogenesis may lead to the creation of more effective and targeted therapeutics with fewer off-target effects.

For instance, on October 27, 2022, GSK plc provided an update on the ContRAst phase III program for otilimab, an investigational monoclonal antibody targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), in the potential treatment of moderate to severe rheumatoid arthritis (RA). The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to or could not tolerate available treatments. ContRAst-1 and ContRAst-2 met their primary endpoints of a statistically significant ACR20 response versus placebo at week 12 in patients with inadequate response to methotrexate (ContRAst-1) and conventional synthetic or biologic DMARDs (ContRAst-2).

Additionally, on May 31, 2023, IGM Biosciences, Inc. released that the U.S. Food and Drug Administration (FDA) cleared two Investigational New Drug (IND) applications for imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager by enabling the initiation of Phase 1b studies in both severe systemic lupus erythematosus (SLE) and severe rheumatoid arthritis (RA). The Company plans to begin patient enrollment in both multicenter clinical studies in the third quarter of 2023.

Further, the increasing prevalence of rheumatoid arthritis, rising regulatory approvals for novel products, increasing clinical trials to develop more therapeutics, increasing awareness about the condition, availability of OTC drugs and increasing technological advancements in the development of novel therapeutics are the factors expected to drive the market over the forecast period.

<h3>Restraints</h3>

Factors such as side effects associated with various types of drugs, lack of better treatment options, high cost associated with various drugs and regulatory challenges are the factors expected to hamper the market.&nbsp;

<h3>Segment Analysis</h3>

The global rheumatoid arthritis drugs market is segmented based on drug class, route of administration, distribution channel and region.

The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment accounted for approximately 43.6% of the rheumatoid arthritis drugs market share

The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is expected to hold the largest market share over the forecast period. NSAIDs can relieve pain and reduce inflammation. Over-the-counter NSAIDs include ibuprofen (Advil, Motrin IB, others) and naproxen sodium (Aleve). Stronger NSAIDs are available by prescription. NSAIDs work by inhibiting the activity of cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins, lipid compounds that mediate inflammation, pain and fever. By blocking COX enzymes, NSAIDs reduce the synthesis of prostaglandins, thereby alleviating pain and inflammation.

For instance, on September 15, 2021, Lupin launched generic Duexis tablets used to treat the symptoms of rheumatoid arthritis and osteoarthritis in the US market. The company has launched an authorized generic version of Horizon Medicines LLC&#39;s Duexis (ibuprofen and famotidine) tablets, 800 mg/26.6 mg.

NSAIDs are primarily used to provide symptomatic relief from pain and inflammation associated with rheumatoid arthritis. They help improve joint function and mobility by allowing patients to better manage their daily activities and maintain quality of life. These drugs also show better efficacy by combined with other drugs.

For instance, on August 04, 2021, Alkem Laboratories launched Ibuprofen and Famotidine tablets, used to relieve the symptoms of rheumatoid arthritis and osteoarthritis, in the US. Alkem Laboratories has launched Ibuprofen and Famotidine tablets in the strength of 800 mg/26.6 mg in the United States, following approval from the United States Food and Drug Administration (USFDA).

<h3>Geographical Analysis</h3>

North America accounted for approximately 42.5% of the market share&nbsp;

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and rising demand for rheumatoid arthritis drugs. North America especially the United States is a very well-known hub for its strong presence of major players such as pharmaceutical companies, which aim to launch a wide range of innovative therapeutics and biosimilars for better management of rheumatoid arthritis in the region.

For instance, on July 04, 2023, Biocon Biologics, a subsidiary of Biocon launched a biosimilar version of AbbVie&#39;s top-selling biologic Humira (generically called adalimumab) in the US market under the brand name HULIO. Adalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie for 2022.&nbsp;

In addition, there is a rising demand for rheumatoid arthritis drugs in the region due to the increasing prevalence of rheumatoid arthritis. For instance, according to Pfizer, more than 30 million American adults, over half of which are under age 65 have osteoarthritis and more than 1.3 million Americans have rheumatoid arthritis.&nbsp;

<h3>Competitive Landscape</h3>

The major global players in the rheumatoid arthritis drugs market include AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Genentech USA, Inc., Pfizer Inc., Amgen Inc., Biogen Inc., Teva Pharmaceutical Industries Limited and Janssen Biotech, Inc. among others.&nbsp;

<h3>COVID-19 Impact Analysis</h3>

The COVID-19 pandemic significantly impacted the global rheumatoid arthritis drugs market. The coronavirus disease 2019 (COVID-19) pandemic has resulted in the reorganization of healthcare settings affecting the delivery of clinical care to patients with rheumatoid arthritis. Patients with rheumatoid arthritis may be at increased risk of COVID-19 infection due to underlying altered immunity, treatment with immunosuppressants including glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) and comorbidities.

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global rheumatoid arthritis drugs market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development</li>
	<li>Excel data sheet with numerous data points of rheumatoid arthritis drugs market-level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as excel consisting of key products of all the major players.</li>
</ul>

The global rheumatoid arthritis drugs market report would provide approximately 61 tables, 60 figures and 187 Pages.

<h3>Target Audience 2024</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Drug Class</li>
		<li>Snippet by Route of Administration</li>
		<li>Snippet by Distribution Channel</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Rising Innovative Product Launches</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Side Effects Associated with the Various Drugs&nbsp;</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Pipeline Analysis</li>
		<li>Unmet Needs</li>
		<li>PESTEL Analysis</li>
		<li>Patent Analysis</li>
		<li>SWOT Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During the Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Drug Class</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Attractiveness Index, By Drug Class</li>
		</ol>
		</li>
		<li>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Corticosteroids</li>
		<li>Disease Modifying Anti-Rheumatic Drugs (DMARDs)</li>
		<li>Biologics</li>
		<li>Analgesics</li>
		<li>Others&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Route of Administration</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Attractiveness Index, By Route of Administration</li>
		</ol>
		</li>
		<li>Oral*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Parenteral&nbsp;</li>
		<li>Others&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Online Pharmacies</li>
		<li>Retail Pharmacies&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>AbbVie Inc.*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Bristol-Myers Squibb Company</li>
		<li>Eli Lilly and Company</li>
		<li>Regeneron Pharmaceuticals, Inc.</li>
		<li>Genentech USA, Inc.</li>
		<li>Pfizer Inc.</li>
		<li>Amgen Inc.</li>
		<li>Biogen Inc.</li>
		<li>Teva Pharmaceutical Industries Limited</li>
		<li>Janssen Biotech, Inc.&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Rheumatoid Arthritis Drugs Market Value, By Drug Class, 2023, 2027 &amp; 2031 (US$ Million)

Table 2 Global Rheumatoid Arthritis Drugs Market Value, By Route of Administration, 2023, 2027 &amp; 2031 (US$ Million)

Table 3 Global Rheumatoid Arthritis Drugs Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 (US$ Million)

Table 4 Global Rheumatoid Arthritis Drugs Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 5 Global Rheumatoid Arthritis Drugs Market Value, By Drug Class, 2023, 2027 &amp; 2031 (US$ Million)

Table 6 Global Rheumatoid Arthritis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 7 Global Rheumatoid Arthritis Drugs Market Value, By Route of Administration, 2023, 2027 &amp; 2031 (US$ Million)

Table 8 Global Rheumatoid Arthritis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 9 Global Rheumatoid Arthritis Drugs Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 (US$ Million)

Table 10 Global Rheumatoid Arthritis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Rheumatoid Arthritis Drugs Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 12 Global Rheumatoid Arthritis Drugs Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Rheumatoid Arthritis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 14 North America Rheumatoid Arthritis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 15 North America Rheumatoid Arthritis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Rheumatoid Arthritis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Rheumatoid Arthritis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 18 South America Rheumatoid Arthritis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 South America Rheumatoid Arthritis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Rheumatoid Arthritis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Rheumatoid Arthritis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 22 Europe Rheumatoid Arthritis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 23 Europe Rheumatoid Arthritis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Rheumatoid Arthritis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Rheumatoid Arthritis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Rheumatoid Arthritis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Rheumatoid Arthritis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Rheumatoid Arthritis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East &amp; Africa Rheumatoid Arthritis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 30 Middle East &amp; Africa Rheumatoid Arthritis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 31 Middle East &amp; Africa Rheumatoid Arthritis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 AbbVie Inc.: Overview

Table 33 AbbVie Inc.: Product Portfolio

Table 34 AbbVie Inc.: Key Developments

Table 35 Bristol-Myers Squibb Company: Overview

Table 36 Bristol-Myers Squibb Company: Product Portfolio

Table 37 Bristol-Myers Squibb Company: Key Developments

Table 38 Eli Lilly and Company: Overview

Table 39 Eli Lilly and Company: Product Portfolio

Table 40 Eli Lilly and Company: Key Developments

Table 41 Regeneron Pharmaceuticals, Inc.: Overview

Table 42 Regeneron Pharmaceuticals, Inc.: Product Portfolio

Table 43 Regeneron Pharmaceuticals, Inc.: Key Developments

Table 44 Genentech USA, Inc.: Overview

Table 45 Genentech USA, Inc.: Product Portfolio

Table 46 Genentech USA, Inc.: Key Developments

Table 47 Pfizer Inc.: Overview

Table 48 Pfizer Inc.: Product Portfolio

Table 49 Pfizer Inc.: Key Developments

Table 50 Amgen Inc.: Overview

Table 51 Amgen Inc.: Product Portfolio

Table 52 Amgen Inc.: Key Developments

Table 53 Biogen Inc.: Overview

Table 54 Biogen Inc.: Product Portfolio

Table 55 Biogen Inc.: Key Developments

Table 56 Teva Pharmaceutical Industries Limited: Overview

Table 57 Teva Pharmaceutical Industries Limited: Product Portfolio

Table 58 Teva Pharmaceutical Industries Limited: Key Developments

Table 59 Janssen Biotech, Inc.: Overview

Table 60 Janssen Biotech, Inc.: Product Portfolio

Table 61 Janssen Biotech, Inc.: Key Developments

List of Figures

Figure 1 Global Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 2 Global Rheumatoid Arthritis Drugs Market Share, By Drug Class, 2022 &amp; 2031 (%)

Figure 3 Global Rheumatoid Arthritis Drugs Market Share, By Route of Administration, 2022 &amp; 2031 (%)

Figure 4 Global Rheumatoid Arthritis Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 5 Global Rheumatoid Arthritis Drugs Market Share, By Region, 2022 &amp; 2031 (%)

Figure 6 Global Rheumatoid Arthritis Drugs Market Y-o-Y Growth, By Drug Class, 2022-2031 (%)

Figure 7 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 8 Corticosteroids Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 9 Disease Modifying Anti-Rheumatic Drugs (DMARDs) Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 10 Biologics Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 11 Analgesics Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 12 Others Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 13 Global Rheumatoid Arthritis Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2031 (%)

Figure 14 Oral Route of Administration in Global Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 15 Parenteral Route of Administration in Global Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 16 Others Route of Administration in Global Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 17 Global Rheumatoid Arthritis Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 18 Hospital Pharmacies Distribution Channel in Global Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 19 Online Pharmacies Distribution Channel in Global Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 20 Retail Pharmacies Distribution Channel in Global Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 21 Global Rheumatoid Arthritis Drugs Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 22 North America Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 23 Asia-Pacific Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 24 Europe Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 25 South America Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 26 Middle East and Africa Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 27 North America Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 28 North America Rheumatoid Arthritis Drugs Market Share, By Drug Class, 2022 &amp; 2031 (%)

Figure 29 North America Rheumatoid Arthritis Drugs Market Share, By Route of Administration, 2022 &amp; 2031 (%)

Figure 30 North America Rheumatoid Arthritis Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 31 North America Rheumatoid Arthritis Drugs Market Share, By Country, 2022 &amp; 2031 (%)

Figure 32 South America Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 33 South America Rheumatoid Arthritis Drugs Market Share, By Drug Class, 2022 &amp; 2031 (%)

Figure 34 South America Rheumatoid Arthritis Drugs Market Share, By Route of Administration, 2022 &amp; 2031 (%)

Figure 35 South America Rheumatoid Arthritis Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 36 South America Rheumatoid Arthritis Drugs Market Share, By Country, 2022 &amp; 2031 (%)

Figure 37 Europe Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 38 Europe Rheumatoid Arthritis Drugs Market Share, By Drug Class, 2022 &amp; 2031 (%)

Figure 39 Europe Rheumatoid Arthritis Drugs Market Share, By Route of Administration, 2022 &amp; 2031 (%)

Figure 40 Europe Rheumatoid Arthritis Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 41 Europe Rheumatoid Arthritis Drugs Market Share, By Country, 2022 &amp; 2031 (%)

Figure 42 Asia-Pacific Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 43 Asia-Pacific Rheumatoid Arthritis Drugs Market Share, By Drug Class, 2022 &amp; 2031 (%)

Figure 44 Asia-Pacific Rheumatoid Arthritis Drugs Market Share, By Route of Administration, 2022 &amp; 2031 (%)

Figure 45 Asia-Pacific Rheumatoid Arthritis Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 46 Asia-Pacific Rheumatoid Arthritis Drugs Market Share, By Country, 2022 &amp; 2031 (%)

Figure 47 Middle East &amp; Africa Rheumatoid Arthritis Drugs Market Value, 2022-2031 (US$ Million)

Figure 48 Middle East &amp; Africa Rheumatoid Arthritis Drugs Market Share, By Drug Class, 2022 &amp; 2031 (%)

Figure 49 Middle East &amp; Africa Rheumatoid Arthritis Drugs Market Share, By Route of Administration, 2022 &amp; 2031 (%)

Figure 50 Middle East &amp; Africa Rheumatoid Arthritis Drugs Market Share, By Distribution Channel, 2022 &amp; 2031 (%)

Figure 51 AbbVie Inc.: Financials

Figure 52 Bristol-Myers Squibb Company: Financials

Figure 53 Eli Lilly and Company: Financials

Figure 54 Regeneron Pharmaceuticals, Inc.: Financials

Figure 55 Genentech USA, Inc.: Financials

Figure 56 Pfizer Inc.: Financials

Figure 57 Amgen Inc.: Financials

Figure 58 Biogen Inc.: Financials

Figure 59 Teva Pharmaceutical Industries Limited: Financials

Figure 60 Janssen Biotech, Inc.: Financials

Rheumatoid Arthritis Drugs Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Biologic Therapeutics Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 19

Starting from

Polymyalgia Rheumatica Treatment Market Size, Share, Industry, and Outlook (2023-2030)

Published: 2023 November 10

Starting from